| Heart disease and stroke statistics—2016 update: a report from the American Heart Association D Mozaffarian, EJ Benjamin, AS Go, DK Arnett, MJ Blaha, M Cushman, ... circulation 133 (4), e38-e360, 2016 | 74644* | 2016 |
| Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study S Yusuf, S Hawken, S Ôunpuu, T Dans, A Avezum, F Lanas, M McQueen, ... The lancet 364 (9438), 937-952, 2004 | 18117 | 2004 |
| Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study S Yusuf, S Hawken, S Ôunpuu, T Dans, A Avezum, F Lanas, M McQueen, ... The lancet 364 (9438), 937-952, 2004 | 18117 | 2004 |
| Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study S Yusuf, S Hawken, S Ôunpuu, T Dans, A Avezum, F Lanas, M McQueen, ... The lancet 364 (9438), 937-952, 2004 | 17091 | 2004 |
| Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study MJ O'donnell, D Xavier, L Liu, H Zhang, SL Chin, P Rao-Melacini, ... The Lancet 376 (9735), 112-123, 2010 | 4263 | 2010 |
| Apixaban in patients with atrial fibrillation SJ Connolly, J Eikelboom, C Joyner, HC Diener, R Hart, S Golitsyn, ... New England Journal of Medicine 364 (9), 806-817, 2011 | 3296 | 2011 |
| Rivaroxaban with or without aspirin in stable cardiovascular disease JW Eikelboom, SJ Connolly, J Bosch, GR Dagenais, RG Hart, ... New England Journal of Medicine 377 (14), 1319-1330, 2017 | 2349 | 2017 |
| Global and regional effects of potentially modifiable risk factors associated with acute stroke in 32 countries (INTERSTROKE): a case-control study MJ O'Donnell, SL Chin, S Rangarajan, D Xavier, L Liu, H Zhang, ... The lancet 388 (10046), 761-775, 2016 | 2130 | 2016 |
| Modifiable risk factors, cardiovascular disease, and mortality in 155 722 individuals from 21 high-income, middle-income, and low-income countries (PURE): a prospective cohort … S Yusuf, P Joseph, S Rangarajan, S Islam, A Mente, P Hystad, M Brauer, ... The Lancet 395 (10226), 795-808, 2020 | 1335 | 2020 |
| Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis … L Wallentin, S Yusuf, MD Ezekowitz, M Alings, M Flather, MG Franzosi, ... The Lancet 376 (9745), 975-983, 2010 | 1292 | 2010 |
| Treatment and prevention of heparin-induced thrombocytopenia: antithrombotic therapy and prevention of thrombosis: American College of Chest Physicians evidence-based clinical … LA Linkins, AL Dans, LK Moores, R Bona, BL Davidson, S Schulman, ... Chest 141 (2), e495S-e530S, 2012 | 1127 | 2012 |
| Investigators IS. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study S Yusuf, S Hawken, S Ounpuu, T Dans, A Avezum, F Lanas, M McQueen, ... Lancet 364 (9438), 937-52, 2004 | 987* | 2004 |
| Dronedarone in high-risk permanent atrial fibrillation SJ Connolly, AJ Camm, JL Halperin, C Joyner, M Alings, J Amerena, ... New England Journal of Medicine 365 (24), 2268-2276, 2011 | 806 | 2011 |
| Blood-pressure lowering in intermediate-risk persons without cardiovascular disease EM Lonn, J Bosch, P López-Jaramillo, J Zhu, L Liu, P Pais, R Diaz, ... New England Journal of Medicine 374 (21), 2009-2020, 2016 | 786 | 2016 |
| Urinary sodium and potassium excretion and risk of cardiovascular events MJ O'Donnell, S Yusuf, A Mente, P Gao, JF Mann, K Teo, M McQueen, ... Jama 306 (20), 2229-2238, 2011 | 702 | 2011 |
| Concomitant use of antiplatelet therapy with dabigatran or warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial AL Dans, SJ Connolly, L Wallentin, S Yang, J Nakamya, M Brueckmann, ... Circulation 127 (5), 634-640, 2013 | 672 | 2013 |
| INTERSTROKE investigators. Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study MJ O’Donnell, D Xavier, L Liu, H Zhang, SL Chin, P Rao-Melacini, ... Lancet 376 (9735), 112-23, 2010 | 577 | 2010 |
| Blood-pressure and cholesterol lowering in persons without cardiovascular disease S Yusuf, E Lonn, P Pais, J Bosch, P Lopez-Jaramillo, J Zhu, D Xavier, ... New England Journal of Medicine 374 (21), 2032-2043, 2016 | 477 | 2016 |
| Association of dairy intake with cardiovascular disease and mortality in 21 countries from five continents (PURE): a prospective cohort study M Dehghan, A Mente, S Rangarajan, P Sheridan, V Mohan, R Iqbal, ... The Lancet 392 (10161), 2288-2297, 2018 | 405* | 2018 |
| Safety of proton pump inhibitors based on a large, multi-year, randomized trial of patients receiving rivaroxaban or aspirin P Moayyedi, JW Eikelboom, J Bosch, SJ Connolly, L Dyal, ... Gastroenterology 157 (3), 682-691. e2, 2019 | 399 | 2019 |
Prof. Denis Xavier MD, MScVice Dean (PG), Professor Pharmacology, Head, Div of Clinical Research, St. John's Medical CollegeVerified email at sjri.res.in
